{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:22:30Z","timestamp":1793877750108,"version":"4.7.0"},"reference-count":221,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Health and Medical Research Council Emerging Leadership Fellow","award":["2008255"],"award-info":[{"award-number":["2008255"]}],"id":[{"id":"https:\/\/ror.org\/011kf5r70","id-type":"ROR","asserted-by":"crossref"}]},{"name":"US Department of Veterans Affairs HSR Award","award":["1IK2HX003866-01A2"],"award-info":[{"award-number":["1IK2HX003866-01A2"]}]},{"name":"Oscar Auerbach Scholars Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acute exacerbations (AEs) occur both in patients with idiopathic pulmonary fibrosis (IPF) and those with non-IPF fibrotic interstitial lung disease (fILD). These events confer high morbidity and mortality, with a lack of proven effective therapeutic interventions. The objective of this state-of-the-art document is to summarize latest evidence since the 2016 International Working Group Report on AE-IPF, expanding it across the spectrum of all fILDs. A comprehensive literature review on the epidemiology, associated and risk factors, prognosis, and management of AE-fILD is summarized. In addition to revising the AE definition and diagnostic criteria for broad application across different fILDs, a conceptual framework for acute respiratory worsening (ARW) has been proposed to encompass a variety of acute respiratory deteriorations, both related and unrelated to AEs. This allows structured evaluation in both clinical and research settings. The proposed revised definition for AE-fILD is an acute respiratory event characterized by increased respiratory symptoms or signs and associated with radiologic or histologic features consistent with diffuse alveolar damage (with or without superimposed organizing pneumonia) in a patient with known or newly diagnosed fILD. On the other hand, ARW refers to a heterogeneous group of clinical events with acute symptom worsening not attributable to diffuse alveolar damage in patients with fILD, such as pulmonary edema, bronchitis, and pneumonia, although severe pneumonia can trigger AE-fILD. Additionally, we discuss considerations for inclusion of AE as a clinical trial endpoint, as well as research priorities for advancing knowledge on the pathogenic mechanisms, event prediction, risk stratification, and development of drugs and supportive treatments.<\/jats:p>","DOI":"10.1093\/ajrccm\/aamag363","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:54:39Z","timestamp":1783770879000},"page":"2358-2385","source":"Crossref","is-referenced-by-count":4,"title":["Acute exacerbation in fibrotic interstitial lung disease: an international working group report"],"prefix":"10.1093","volume":"212","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5434-9342","authenticated-orcid":false,"given":"Yet H","family":"Khor","sequence":"first","affiliation":[{"name":"Respiratory Research@Alfred, School of Translational Medicine, Monash University , Melbourne, Victoria,","place":["Australia"]},{"name":"Department of Respiratory and Sleep Medicine, Austin Health , Heidelberg, Victoria,","place":["Australia"]},{"name":"Institute for Breathing and Sleep , Heidelberg, Victoria,","place":["Australia"]},{"name":"Faculty of Medicine, University of Melbourne , Melbourne, Victoria,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5775-5947","authenticated-orcid":false,"given":"Fabrizio","family":"Luppi","sequence":"additional","affiliation":[{"name":"Respiratory Diseases Unit, School of Medicine and Surgery, University of Milano-Bicocca. Fondazione IRCCS \u201cSan Gerardo dei Tintori,\u201d Monza,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7015-9610","authenticated-orcid":false,"given":"Ayodeji","family":"Adegunsoye","sequence":"additional","affiliation":[{"name":"Section of Pulmonary and Critical Care, Department of Medicine, University of Chicago , Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget F","family":"Collins","sequence":"additional","affiliation":[{"name":"Center for Interstitial Lung Diseases, Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5878-1952","authenticated-orcid":false,"given":"Erica","family":"Farrand","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Division of Clinical Informatics and Digital Transformation, Department of Medicine, University of California, San Francisco , San Francisco, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney B","family":"Montesi","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5256-9029","authenticated-orcid":false,"given":"Chad A","family":"Newton","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center , Dallas, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-0955","authenticated-orcid":false,"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[{"name":"National Coordinating Reference Centre for Rare Pulmonary Diseases, OrphaLung, Louis Pradel Hospital, Hospices Civils de Lyon, ERN-LUNG , Lyon,","place":["France"]},{"name":"UMR 754, Claude Bernard University Lyon 1, INRAE , Lyon,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1205-5511","authenticated-orcid":false,"given":"Kerri A","family":"Johannson","sequence":"additional","affiliation":[{"name":"Department of Medicine and Snyder Institute for Chronic Diseases, University of Calgary , Calgary, Alberta,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1325-8820","authenticated-orcid":false,"given":"Bhavika","family":"Kaul","sequence":"additional","affiliation":[{"name":"Veterans Affairs Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey Veterans Affairs Medical Center , Houston, TX,","place":["United States"]},{"name":"Section of Pulmonary\/Critical Care Medicine and Health Services Research, Department of Medicine, Baylor College of Medicine , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kolb","sequence":"additional","affiliation":[{"name":"Department of Medicine, Firestone Institute for Respiratory Health, McMaster University , Hamilton, Ontario,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[{"name":"Mainz Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center, and Department of Pulmonary, Critical Care and Sleep Medicine, Marienhaus Clinic Mainz , Mainz,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1301-8800","authenticated-orcid":false,"given":"Philip L","family":"Molyneaux","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London , London,","place":["United Kingdom"]},{"name":"Royal Brompton and Harefield Hospitals, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-6962","authenticated-orcid":false,"given":"Marlies S","family":"Wijsenbeek","sequence":"additional","affiliation":[{"name":"Centre of Expertise for Interstitial Lung Diseases and Sarcoidosis, Department of Respiratory Medicine, Erasmus MC , Rotterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Antoniou","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular and Cellular Pneumonology, Department of Respiratory Medicine, School of Medicine, University of Crete , Heraklion,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Behr","sequence":"additional","affiliation":[{"name":"Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center, German Center for Lung Research (DZL) , Munich,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4238-6963","authenticated-orcid":false,"given":"Elisabeth","family":"Bendstrup","sequence":"additional","affiliation":[{"name":"Centre for Rare Lung Diseases, Department of Respiratory Diseases and Allergy, Aarhus University Hospital , Aarhus,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Aarhus University , Aarhus,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8384-9506","authenticated-orcid":false,"given":"Harold R","family":"Collard","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California, San Francisco , San Francisco, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5076-8929","authenticated-orcid":false,"given":"Tamera J","family":"Corte","sequence":"additional","affiliation":[{"name":"Respiratory and Sleep Medicine, Royal Prince Alfred Hospital , Camperdown, New South Wales,","place":["Australia"]},{"name":"Faculty of Medicine and Health, University of Sydney , Sydney, New South Wales,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9406-3130","authenticated-orcid":false,"given":"Wonder P","family":"Drake","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Maryland School of Medicine , Baltimore, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3807-3315","authenticated-orcid":false,"given":"Giovanni","family":"Ferrara","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, and Alberta Health Services , Edmonton, Alberta,","place":["Canada"]},{"name":"Digital Health Unit, Clinical Trial Office, University of Alberta , Edmonton, Alberta,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6190-624X","authenticated-orcid":false,"given":"Lida P","family":"Hariri","sequence":"additional","affiliation":[{"name":"Department of Pathology and Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory M","family":"Hogaboam","sequence":"additional","affiliation":[{"name":"Women\u2019s Guild Lung Institute, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Cedars-Sinai Medical Center , Los Angeles, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-2119","authenticated-orcid":false,"given":"R Gisli","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naftali","family":"Kaminski","sequence":"additional","affiliation":[{"name":"Pulmonary, Critical Care, and Sleep Medicine, Yale School of Medicine , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5859-8744","authenticated-orcid":false,"given":"Ella A","family":"Kazerooni","sequence":"additional","affiliation":[{"name":"Departments of Radiology and Internal Medicine, University of Michigan , Ann Arbor, MI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4507-0742","authenticated-orcid":false,"given":"Michael P","family":"Keane","sequence":"additional","affiliation":[{"name":"School of Medicine, University College Dublin , Dublin,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-5459","authenticated-orcid":false,"given":"Yasuhiro","family":"Kondoh","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Allergology, Aichi Medical University , Nagakute,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5758-8365","authenticated-orcid":false,"given":"Joyce S","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Colorado Anschutz Medical Center , Aurora, CO,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9267-3437","authenticated-orcid":false,"given":"Fengming","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University , Chengdu,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7192-9149","authenticated-orcid":false,"given":"Toby M","family":"Maher","sequence":"additional","affiliation":[{"name":"Keck School of Medicine, University of Southern California , Los Angeles, CA,","place":["United States"]},{"name":"National Heart and Lung Institute, Imperial College London , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando J","family":"Martinez","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, UMass Chan Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuben","family":"Moodley","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, University of Western Australia , Nedlands, Western Australia,","place":["Australia"]},{"name":"Department of Respiratory Medicine, Fiona Stanley Hospital , Murdoch, Western Australia,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8594-1448","authenticated-orcid":false,"given":"Luca","family":"Richeldi","sequence":"additional","affiliation":[{"name":"Unit\u00e0 Operativa Complessa di Pneumologia, Universitas Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Rome,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1294-6421","authenticated-orcid":false,"given":"Marco","family":"Sebastiani","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Azienda Unit\u00e0 Sanitaria Locale di Piacenza , Piacenza,","place":["Italy"]},{"name":"Department of Medicine and Surgery, University of Parma , Parma,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5101-634X","authenticated-orcid":false,"given":"Patricia J","family":"Sime","sequence":"additional","affiliation":[{"name":"Department of Medicine, Virginia Commonwealth University , Richmond, VA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6013-0225","authenticated-orcid":false,"given":"Susanne","family":"Stowasser","sequence":"additional","affiliation":[{"name":"Global Clinical Development, Boehringer Ingelheim International , Ingelheim am Rhein,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Tomassetti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Careggi University Hospital , Florence,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athol","family":"Wells","sequence":"additional","affiliation":[{"name":"Interstitial Lung Disease Unit, Royal Brompton Hospital, Guy's and St Thomas\u2019 National Health Service Foundation Trust , London,","place":["United Kingdom"]},{"name":"Margaret Turner Warwick Centre for Fibrosing Lung Disease, National Heart and Lung Institute, Imperial College London, London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1049-393X","authenticated-orcid":false,"given":"Christopher J","family":"Ryerson","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of British Columbia , Vancouver, British Columbia,","place":["Canada"]},{"name":"Centre for Heart Lung Innovation, St. Paul\u2019s Hospital , Vancouver, British Columbia,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9559-1485","authenticated-orcid":false,"given":"Anna J","family":"Podolanczuk","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medicine , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"2026093006115125000_aamag363-B1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report","volume":"194","author":"Collard","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006115125000_aamag363-B2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026093006115125000_aamag363-B3","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1136\/thorax-2022-219795","article-title":"Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety","volume":"78","author":"Fern\u00e1ndez P\u00e9rez","year":"2023","journal-title":"Thorax"},{"key":"2026093006115125000_aamag363-B4","doi-asserted-by":"publisher","first-page":"00403","DOI":"10.1183\/23120541.00403-2024","article-title":"Acute exacerbations in patients with progressive pulmonary fibrosis","volume":"10","author":"Kreuter","year":"2024","journal-title":"ERJ Open Res"},{"key":"2026093006115125000_aamag363-B5","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"2026093006115125000_aamag363-B6","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","article-title":"Nerandomilast in patients with progressive pulmonary fibrosis","volume":"392","author":"Maher","year":"2025","journal-title":"N Engl J Med"},{"key":"2026093006115125000_aamag363-B7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13054-018-2002-4","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: lessons learned from acute respiratory distress syndrome?","volume":"22","author":"Marchioni","year":"2018","journal-title":"Critical Care"},{"key":"2026093006115125000_aamag363-B8","doi-asserted-by":"publisher","first-page":"eaba1983","DOI":"10.1126\/sciadv.aba1983","article-title":"Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis","volume":"6","author":"Adams","year":"2020","journal-title":"Sci Adv"},{"key":"2026093006115125000_aamag363-B9","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1164\/rccm.201712-2410OC","article-title":"Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis","volume":"199","author":"Reyfman","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006115125000_aamag363-B10","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1164\/rccm.202306-0979OC","article-title":"Single-cell profiling reveals immune aberrations in progressive idiopathic pulmonary fibrosis","volume":"210","author":"Unterman","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006115125000_aamag363-B11","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1152\/physrev.00004.2016","article-title":"Idiopathic pulmonary fibrosis: a genetic disease that involves mucociliary dysfunction of the peripheral airways","volume":"96","author":"Evans","year":"2016","journal-title":"Physiol Rev"},{"key":"2026093006115125000_aamag363-B12","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1164\/rccm.201809-1650OC","article-title":"Lung microbiota contribute to pulmonary inflammation and disease progression in pulmonary fibrosis","volume":"199","author":"O\u2019Dwyer","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006115125000_aamag363-B13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1164\/rccm.200810-1596OC","article-title":"Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis","volume":"180","author":"Konishi","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006115125000_aamag363-B14","doi-asserted-by":"publisher","first-page":"e0133684","DOI":"10.1371\/journal.pone.0127771","article-title":"Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis","volume":"10","author":"Donahoe","year":"2015","journal-title":"PLoS One"},{"key":"2026093006115125000_aamag363-B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.rmed.2016.05.012","article-title":"Angiopoietin-2 expression in patients with an acute exacerbation of idiopathic interstitial pneumonias","volume":"117","author":"Ando","year":"2016","journal-title":"Respir Med"},{"key":"2026093006115125000_aamag363-B16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13000-016-0583-2","article-title":"Plasma microRNAs are associated with acute exacerbation in idiopathic pulmonary fibrosis","volume":"11","author":"Min","year":"2016","journal-title":"Diagn Pathol"},{"key":"2026093006115125000_aamag363-B17","doi-asserted-by":"publisher","first-page":"891448","DOI":"10.3389\/fimmu.2022.891448","article-title":"Elevated expression of growth differentiation factor-15 is associated with acute exacerbation of idiopathic pulmonary fibrosis","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol"},{"key":"2026093006115125000_aamag363-B18","doi-asserted-by":"publisher","first-page":"642855","DOI":"10.3389\/fimmu.2021.642855","article-title":"The NLRP3-inflammasome-caspase-1 pathway is upregulated in idiopathic pulmonary fibrosis and acute exacerbations and is inducible by apoptotic A549 cells","volume":"12","author":"J\u00e4ger","year":"2021","journal-title":"Front Immunol"},{"key":"2026093006115125000_aamag363-B19","doi-asserted-by":"publisher","first-page":"e0116775","DOI":"10.1371\/journal.pone.0116775","article-title":"Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis","volume":"10","author":"Schupp","year":"2015","journal-title":"PLoS One"},{"key":"2026093006115125000_aamag363-B20","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.cyto.2017.08.019","article-title":"High levels of IL-6 and IL-8 characterize early-on idiopathic pulmonary fibrosis acute exacerbations","volume":"102","author":"Papiris","year":"2018","journal-title":"Cytokine"},{"key":"2026093006115125000_aamag363-B21","doi-asserted-by":"publisher","first-page":"000889","DOI":"10.1136\/bmjresp-2021-000889","article-title":"Prognostic significance of serum cytokines during acute exacerbation of idiopathic interstitial pneumonias treated with thrombomodulin","volume":"8","author":"Arai","year":"2021","journal-title":"BMJ Open Respir Res"},{"key":"2026093006115125000_aamag363-B22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.intimp.2019.02.039","article-title":"Prognostic value of IFN-\u03b3, sCD163, CCL2 and CXCL10 involved in acute exacerbation of idiopathic pulmonary fibrosis","volume":"70","author":"Gui","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"2026093006115125000_aamag363-B23","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.resinv.2021.05.008","article-title":"Serum S100A8 and S100A9 as prognostic biomarkers in acute exacerbation of idiopathic pulmonary fibrosis","volume":"59","author":"Tanaka","year":"2021","journal-title":"Respir Investig"},{"key":"2026093006115125000_aamag363-B24","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1165\/rcmb.2023-0054LE","article-title":"Variations in S100A8\/A12 gene expression are associated with the efficacy of nintedanib and acute exacerbation development in idiopathic pulmonary fibrosis patients","volume":"69","author":"Arai","year":"2023","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026093006115125000_aamag363-B25","doi-asserted-by":"publisher","first-page":"6940480","DOI":"10.1155\/2016\/6940480","article-title":"Plasma leptin is elevated in acute exacerbation of idiopathic pulmonary fibrosis","volume":"2016","author":"Cao","year":"2016","journal-title":"Mediators Inflamm"},{"key":"2026093006115125000_aamag363-B26","doi-asserted-by":"publisher","first-page":"10484","DOI":"10.1038\/s41598-019-46990-3","article-title":"Analysis of serum adiponectin and leptin in patients with acute exacerbation of idiopathic pulmonary fibrosis","volume":"9","author":"Enomoto","year":"2019","journal-title":"Sci Rep"},{"key":"2026093006115125000_aamag363-B27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00408-025-00800-y","article-title":"Serum soluble toll-like receptor 4 is a predictive biomarker for acute exacerbation and prognosis of idiopathic pulmonary fibrosis: a retrospective study","volume":"203","author":"Kitadai","year":"2025","journal-title":"Lung"},{"key":"2026093006115125000_aamag363-B28","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/resp.12995","article-title":"AGER gene polymorphisms and soluble receptor for advanced glycation end product in patients with idiopathic pulmonary fibrosis","volume":"22","author":"Yamaguchi","year":"2017","journal-title":"Respirology"},{"key":"2026093006115125000_aamag363-B29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12931-017-0511-3","article-title":"Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis","volume":"18","author":"Molyneaux","year":"2017","journal-title":"Respir Res"},{"key":"2026093006115125000_aamag363-B30","doi-asserted-by":"publisher","first-page":"1479973119869334","DOI":"10.1177\/1479973119869334","article-title":"Acute exacerbations of idiopathic pulmonary fibrosis: does clinical stratification or steroid treatment matter?","volume":"16","author":"Cuerpo","year":"2019","journal-title":"Chron Respir Dis"},{"key":"2026093006115125000_aamag363-B31","doi-asserted-by":"publisher","first-page":"100011","DOI":"10.1016\/j.jhlto.2023.100011","article-title":"Lung transplantation during acute exacerbations of interstitial lung disease and post-transplant survival","volume":"2","author":"Guidot","year":"2023","journal-title":"JHLT Open"},{"key":"2026093006115125000_aamag363-B32","first-page":"OC06","article-title":"Significant bacterial isolates in patients presenting with acute exacerbation of idiopathic pulmonary fibrosis","volume":"12","author":"Harish","year":"2018","journal-title":"J Clin Diagn Res"},{"key":"2026093006115125000_aamag363-B33","doi-asserted-by":"publisher","first-page":"e2022038","DOI":"10.36141\/svdld.v39i4.13682","article-title":"Intravenous immunoglobulin for acute exacerbation of fibrotic idiopathic interstitial pneumonias","volume":"39","author":"Higo","year":"2022","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026093006115125000_aamag363-B34","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/qjmed\/hcaa214","article-title":"Utility of illness severity scores to predict mortality in patients hospitalized with respiratory deterioration of idiopathic pulmonary fibrosis","volume":"114","author":"Hyams","year":"2021","journal-title":"QJM"},{"key":"2026093006115125000_aamag363-B35","first-page":"5762","article-title":"Corticosteroid responsiveness in patients with acute exacerbation of interstitial lung disease admitted to the emergency department","volume":"11","author":"Jang","year":"2021","journal-title":"Sci"},{"key":"2026093006115125000_aamag363-B36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5152\/eurasianjmed.2018.17330","article-title":"Clinical characteristics based on the new criteria of acute exacerbation in patients with idiopathic pulmonary fibrosis","volume":"50","author":"Kishaba","year":"2018","journal-title":"Eurasian J Med"},{"key":"2026093006115125000_aamag363-B37","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.resinv.2017.05.001","article-title":"Direct hemoperfusion with polymyxin B\u2013immobilized fiber for the treatment of the acute exacerbation of idiopathic pulmonary fibrosis in patients requiring invasive mechanical ventilation","volume":"55","author":"Komatsu","year":"2017","journal-title":"Respir Investig"},{"key":"2026093006115125000_aamag363-B38","doi-asserted-by":"publisher","first-page":"106534","DOI":"10.1016\/j.rmed.2021.106534","article-title":"Prognostic significance of bronchoalveolar lavage cellular analysis in patients with acute exacerbation of interstitial lung disease","volume":"186","author":"Kono","year":"2021","journal-title":"Respir Med"},{"key":"2026093006115125000_aamag363-B39","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.chest.2022.01.007","article-title":"Acute respiratory deterioration in rheumatoid arthritis\u2013associated interstitial lung disease: a single-center study","volume":"162","author":"Kwon","year":"2022","journal-title":"Chest"},{"key":"2026093006115125000_aamag363-B40","doi-asserted-by":"publisher","first-page":"801206","DOI":"10.3389\/fmed.2021.801206","article-title":"Treatment outcomes of infectious and non-infectious acute exacerbation of myositis-related interstitial lung disease","volume":"8","author":"Lee","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026093006115125000_aamag363-B41","first-page":"1033","article-title":"Bacteriological profile of acute exacerbation of IPF","volume":"15","author":"Sharma","year":"2023","journal-title":"Int J Pharm Clin Res"},{"key":"2026093006115125000_aamag363-B42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/jcm13195733","article-title":"Clinical evaluation of acute exacerbation of interstitial lung disease in a single tertiary center: perspectives before and after the coronavirus disease 2019 pandemic","volume":"13","author":"Takagi","year":"2024","journal-title":"J Clin Med"},{"key":"2026093006115125000_aamag363-B43","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.rmed.2018.09.011","article-title":"Outcomes with newly proposed classification of acute respiratory deterioration in idiopathic pulmonary fibrosis","volume":"143","author":"Teramachi","year":"2018","journal-title":"Respir Med"},{"key":"2026093006115125000_aamag363-B44","doi-asserted-by":"publisher","first-page":"5160694","DOI":"10.1155\/2019\/5160694","article-title":"The role of infection in acute exacerbation of idiopathic pulmonary fibrosis","volume":"2019","author":"Weng","year":"2019","journal-title":"Mediators Inflamm"},{"key":"2026093006115125000_aamag363-B45","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/s12890-024-03216-1","article-title":"Value of bronchoalveolar lavage fluid metagenomic next-generation sequencing in acute exacerbation of fibrosing interstitial lung disease: an individualized treatment protocol based on microbiological evidence","volume":"24","author":"Zhan","year":"2024","journal-title":"BMC Pulm Med"},{"key":"2026093006115125000_aamag363-B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hrtlng.2024.03.007","article-title":"Infectious respiratory pathogens among patients with acute exacerbation of idiopathic pulmonary fibrosis during the coronavirus disease 2019 pandemic in Japan","volume":"67","author":"Akata","year":"2024","journal-title":"Heart Lung"},{"key":"2026093006115125000_aamag363-B47","first-page":"9","article-title":"Clinical characteristics of acute exacerbations of idiopathic pulmonary fibrosis and involvement of viral, Mycoplasma pneumoniae, and Chlamydophila pneumoniae infections","volume":"40","author":"Anzai","year":"2013","journal-title":"Dokkyo J Med Sci"},{"key":"2026093006115125000_aamag363-B48","doi-asserted-by":"publisher","first-page":"815924","DOI":"10.3389\/fmed.2022.815924","article-title":"COVID-19-triggered acute exacerbation of IPF, an underdiagnosed clinical entity with two-peaked respiratory failure: a case report and literature review","volume":"9","author":"Goto","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026093006115125000_aamag363-B49","doi-asserted-by":"publisher","first-page":"101615","DOI":"10.1016\/j.rmcr.2022.101615","article-title":"Clinical importance of serum heme oxygenase-1 measurement in patients with acute exacerbation of idiopathic pulmonary fibrosis triggered by coronavirus disease 2019","volume":"36","author":"Hara","year":"2022","journal-title":"Respir Med Case Rep"},{"key":"2026093006115125000_aamag363-B50","doi-asserted-by":"publisher","first-page":"e23411","DOI":"10.7759\/cureus.23411","article-title":"Tocilizumab and baricitinib for recovery from acute exacerbation of combined pulmonary fibrosis and emphysema secondary to COVID-19 infection: a case report","volume":"14","author":"Kai","year":"2022","journal-title":"Cureus"},{"key":"2026093006115125000_aamag363-B51","doi-asserted-by":"publisher","DOI":"10.1186\/s43055-021-00431-2","article-title":"COVID-19 causing acute deterioration of interstitial lung disease: a case report","volume":"52","author":"Kathar Hussain","year":"2021","journal-title":"Egypt J Radiol Nucl Med"},{"key":"2026093006115125000_aamag363-B52","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12931-019-1247-z","article-title":"Prognostic differences among patients with idiopathic interstitial pneumonias with acute exacerbation of varying pathogenesis: a retrospective study","volume":"20","author":"Kato","year":"2019","journal-title":"Respir Res"},{"key":"2026093006115125000_aamag363-B53","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.resinv.2021.06.007","article-title":"COVID-19 and acute exacerbation of interstitial lung disease","volume":"59","author":"Kondoh","year":"2021","journal-title":"Respir Investig"},{"key":"2026093006115125000_aamag363-B54","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/resp.14763","article-title":"Steroid therapy in acute exacerbation of fibrotic interstitial lung disease","volume":"29","author":"Koshy","year":"2024","journal-title":"Respirology"},{"key":"2026093006115125000_aamag363-B55","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.21037\/jtd-20-1658","article-title":"Coronavirus disease 2019 pneumonia may present as an acute exacerbation of idiopathic pulmonary fibrosis","volume":"12","author":"Lee","year":"2020","journal-title":"J Thorac Dis"},{"key":"2026093006115125000_aamag363-B56","first-page":"396","article-title":"Successful treatment of infection-triggered acute exacerbation of idiopathic pulmonary fibrosis with corticosteroids combined with macrolides","volume":"30","author":"Ohe","year":"2019","journal-title":"Gazi Med J"},{"key":"2026093006115125000_aamag363-B57","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2169\/internalmedicine.8163-21","article-title":"Successful treatment with high-dose steroids for acute exacerbation of idiopathic pulmonary fibrosis triggered by COVID-19","volume":"61","author":"Omote","year":"2022","journal-title":"Intern Med"},{"key":"2026093006115125000_aamag363-B58","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.resinv.2020.06.006","article-title":"Prevalence of viral infection in acute exacerbation of interstitial lung diseases in Japan","volume":"58","author":"On","year":"2020","journal-title":"Respir Investig"},{"key":"2026093006115125000_aamag363-B59","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/qjmed\/hcad021","article-title":"Exacerbation of hypersensitivity pneumonitis induced by COVID-19","volume":"116","author":"Sumi","year":"2023","journal-title":"QJM"},{"key":"2026093006115125000_aamag363-B60","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.2169\/internalmedicine.2413-18","article-title":"Fatal acute exacerbation of familial interstitial pneumonia complicated with dyskeratosis congenita after influenza virus B infection","volume":"58","author":"Tachiwada","year":"2019","journal-title":"Intern Med"},{"key":"2026093006115125000_aamag363-B61","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.resinv.2013.07.005","article-title":"Viral infections in patients with an acute exacerbation of idiopathic interstitial pneumonia","volume":"52","author":"Ushiki","year":"2014","journal-title":"Respir Investig"},{"key":"2026093006115125000_aamag363-B62","doi-asserted-by":"publisher","first-page":"1753466619847130","DOI":"10.1177\/1753466619847130","article-title":"High-flow nasal cannula oxygen therapy to treat acute respiratory failure in patients with acute exacerbation of idiopathic pulmonary fibrosis","volume":"13","author":"Vianello","year":"2019","journal-title":"Ther Adv Respir Dis"},{"key":"2026093006115125000_aamag363-B63","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1164\/rccm.201010-1752OC","article-title":"Viral infection in acute exacerbation of idiopathic pulmonary fibrosis","volume":"183","author":"Wootton","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006115125000_aamag363-B64","doi-asserted-by":"publisher","first-page":"101857","DOI":"10.1016\/j.rmcr.2023.101857","article-title":"Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease triggered by COVID-19: what is the best practice for treatment?","volume":"43","author":"Yonezawa","year":"2023","journal-title":"Respir Med Case Rep"},{"key":"2026093006115125000_aamag363-B65","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s13104-016-2052-0","article-title":"Acute exacerbation of interstitial pneumonia associated with rheumatoid arthritis during the course of treatment for Pneumocystis jirovecii pneumonia: a case report","volume":"9","author":"Kuroda","year":"2016","journal-title":"BMC Res Notes"},{"key":"2026093006115125000_aamag363-B66","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12931-014-0109-y","article-title":"Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis","volume":"15","author":"Oda","year":"2014","journal-title":"Respir Res"},{"key":"2026093006115125000_aamag363-B67","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.rmcr.2018.01.004","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis triggered by Aspergillus empyema","volume":"23","author":"Suzuki","year":"2018","journal-title":"Respir Med Case Rep"},{"key":"2026093006115125000_aamag363-B68","doi-asserted-by":"publisher","first-page":"101","DOI":"10.5603\/ARM.a2021.0012","article-title":"Risk factors for acute exacerbation following bronchoalveolar lavage in patients with suspected idiopathic pulmonary fibrosis: a retrospective cohort study","volume":"89","author":"Abe","year":"2021","journal-title":"Adv Respir Med"},{"key":"2026093006115125000_aamag363-B69","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1620\/tjem.174.379","article-title":"Bron\u00adchoalveolar lavage as a possible cause of acute exacer\u00adbation in idiopathic pulmonary fibrosis patients","volume":"174","author":"Hiwatari","year":"1994","journal-title":"Tohoku J Exp Med"},{"key":"2026093006115125000_aamag363-B70","doi-asserted-by":"publisher","first-page":"929A","DOI":"10.1378\/chest.1108443","article-title":"Acute exacerbation of IPF following bronchoalveolar lavage procedures","volume":"140","author":"Sakamoto","year":"2011","journal-title":"Chest Conf CHEST"},{"key":"2026093006115125000_aamag363-B71","doi-asserted-by":"publisher","first-page":"e01427","DOI":"10.1002\/rcr2.1427","article-title":"18F-FDG accumulation at the early onset of acute exacerbation of idiopathic interstitial pneumonia on 18F-FDG PET\/CT: a case report","volume":"12","author":"Akaike","year":"2024","journal-title":"Respirol Case Rep"},{"key":"2026093006115125000_aamag363-B72","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/jjco\/hyz115","article-title":"Risk factors for acute exacerbation of idiopathic interstitial pneumonia in patients undergoing lung cancer treatment","volume":"49","author":"Taya","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"2026093006115125000_aamag363-B73","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/resp.14678","article-title":"Low bleeding rates following transbronchial lung cryobiopsy in unclassifiable interstitial lung disease","volume":"29","author":"Taverner","year":"2024","journal-title":"Respirology"},{"key":"2026093006115125000_aamag363-B74","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12890-019-0780-3","article-title":"Diagnostic yield and risk\/benefit analysis of trans-bronchial lung cryobiopsy in diffuse parenchymal lung diseases: a large cohort of 699 patients","volume":"19","author":"Ravaglia","year":"2019","journal-title":"BMC Pulm Med"},{"key":"2026093006115125000_aamag363-B75","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1164\/rccm.201504-0711OC","article-title":"Bronchoscopic lung cryobiopsy increases diagnostic confidence in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis","volume":"193","author":"Tomassetti","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006115125000_aamag363-B76","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12931-016-0400-1","article-title":"Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis","volume":"17","author":"Kakugawa","year":"2016","journal-title":"Respir Res"},{"key":"2026093006115125000_aamag363-B77","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.21037\/jtd.2016.03.89","article-title":"Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status","volume":"8","author":"Kishaba","year":"2016","journal-title":"J Thorac Dis"},{"key":"2026093006115125000_aamag363-B78","doi-asserted-by":"publisher","first-page":"e11683","DOI":"10.1097\/MD.0000000000011683","article-title":"Presence of lung cancer and high gender, age, and physiology score as predictors of acute exacerbation in combined pulmonary fibrosis and emphysema: a retrospective study","volume":"97","author":"Oh","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2026093006115125000_aamag363-B79","doi-asserted-by":"publisher","first-page":"1479973120909840","DOI":"10.1177\/1479973120909840","article-title":"Monocyte count and the risk for acute exacerbation of fibrosing interstitial lung disease: a retrospective cohort study","volume":"17","author":"Kawamura","year":"2020","journal-title":"Chron Respir Dis"},{"key":"2026093006115125000_aamag363-B80","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12890-023-02735-7","article-title":"Cluster features in fibrosing interstitial lung disease and associations with prognosis","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Pulm Med"},{"key":"2026093006115125000_aamag363-B81","doi-asserted-by":"publisher","first-page":"39","DOI":"10.36141\/svdld.v36i1.7117","article-title":"Newly defined acute exacerbation of idiopathic pulmonary fibrosis with surgically-proven usual interstitial pneumonia: risk factors and outcome","volume":"36","author":"Okuda","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026093006115125000_aamag363-B82","doi-asserted-by":"publisher","first-page":"178","DOI":"10.4103\/atm.atm_14_21","article-title":"Acute exacerbation in interstitial lung disease","volume":"16","author":"Alhamad","year":"2021","journal-title":"Ann Thorac Med"},{"key":"2026093006115125000_aamag363-B83","doi-asserted-by":"publisher","first-page":"e0255365","DOI":"10.1371\/journal.pone.0255365","article-title":"The role of interleukin-6 as a prognostic biomarker for predicting acute exacerbation in interstitial lung diseases","volume":"16","author":"Lee","year":"2021","journal-title":"PLoS One"},{"key":"2026093006115125000_aamag363-B84","doi-asserted-by":"publisher","first-page":"278","DOI":"10.21037\/jtd-21-1418","article-title":"Platelet-derived growth factor can predict survival and acute exacerbation in patients with idiopathic pulmonary fibrosis","volume":"14","author":"Arai","year":"2022","journal-title":"J Thorac Dis"},{"key":"2026093006115125000_aamag363-B85","first-page":"103","article-title":"Risk factors of acute exacerbation of idiopathic pulmonary fibrosis","volume":"27","author":"Kondoh","year":"2010","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026093006115125000_aamag363-B86","doi-asserted-by":"publisher","first-page":"e001864","DOI":"10.1136\/bmjresp-2023-001864","article-title":"Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry","volume":"10","author":"Tsubouchi","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"2026093006115125000_aamag363-B87","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1111\/resp.12862","article-title":"Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial pneumonia","volume":"21","author":"Arai","year":"2016","journal-title":"Respirology"},{"key":"2026093006115125000_aamag363-B88","doi-asserted-by":"publisher","first-page":"8817","DOI":"10.1038\/s41598-022-12693-5","article-title":"Impact of the revised definition on incidence and outcomes of acute exacerbation of idiopathic pulmonary fibrosis","volume":"12","author":"Yoo","year":"2022","journal-title":"Sci Rep"},{"key":"2026093006115125000_aamag363-B89","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.resinv.2019.07.003","article-title":"Prognostic impact of an early marginal decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone","volume":"57","author":"Kono","year":"2019","journal-title":"Respir Investig"},{"key":"2026093006115125000_aamag363-B90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/23120541.00261-2019","article-title":"Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis","volume":"6","author":"Dotan","year":"2020","journal-title":"ERJ Open Res"},{"key":"2026093006115125000_aamag363-B91","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.resinv.2015.04.005","article-title":"Risk factors for acute exacerbation of idiopathic pulmonary fibrosis-extended analysis of pirfenidone trial in Japan","volume":"53","author":"Kondoh","year":"2015","journal-title":"Respir Investig"},{"key":"2026093006115125000_aamag363-B92","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1093\/rheumatology\/keaa608","article-title":"Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: clinical features and prognosis","volume":"60","author":"Izuka","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026093006115125000_aamag363-B93","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12931-021-01748-2","article-title":"Acute exacerbation of fibrotic hypersensitivity pneumonitis: incidence and outcomes","volume":"22","author":"Kang","year":"2021","journal-title":"Respir Res"},{"key":"2026093006115125000_aamag363-B94","doi-asserted-by":"publisher","first-page":"1802465","DOI":"10.1183\/13993003.02465-2018","article-title":"Probable usual interstitial pneumonia pattern on chest CT: is it sufficient for a diagnosis of idiopathic pulmonary fibrosis?","volume":"55","author":"Fukihara","year":"2020","journal-title":"Eur Respir J"},{"key":"2026093006115125000_aamag363-B95","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12890-024-03172-w","article-title":"Identification of risk factors for acute exacerbation of idiopathic pulmonary fibrosis based on baseline high-resolution computed tomography: a prospective observational study","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Pulm Med"},{"key":"2026093006115125000_aamag363-B96","doi-asserted-by":"publisher","first-page":"2201634","DOI":"10.1183\/13993003.01634-2022","article-title":"A predictive model for acute exacerbation of idiopathic interstitial pneumonias","volume":"61","author":"Karayama","year":"2023","journal-title":"Eur Respir J"},{"key":"2026093006115125000_aamag363-B97","first-page":"2887","article-title":"Association between environment pollution exposure and exacerbation in patients with interstitial lung disease","volume":"16","author":"Mohanty","year":"2024","journal-title":"Int J Pharm Clin Res"},{"key":"2026093006115125000_aamag363-B98","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12931-021-01671-6","article-title":"Exposure to PM2.5 is a risk factor for acute exacerbation of surgically diagnosed idiopathic pulmonary fibrosis: a case-control study","volume":"22","author":"Tahara","year":"2021","journal-title":"Respir Res"},{"key":"2026093006115125000_aamag363-B99","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12940-021-00786-z","article-title":"Long-term personal air pollution exposure and risk for acute exacerbation of idiopathic pulmonary fibrosis","volume":"20","author":"Tomos","year":"2021","journal-title":"Environ Health"},{"key":"2026093006115125000_aamag363-B100","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1183\/09031936.00122213","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure","volume":"43","author":"Johannson","year":"2014","journal-title":"Eur Respir J"},{"key":"2026093006115125000_aamag363-B101","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1136\/thoraxjnl-2017-209967","article-title":"Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis","volume":"73","author":"Sese","year":"2018","journal-title":"Thorax"},{"key":"2026093006115125000_aamag363-B102","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/ijerph192416689","article-title":"Prognosis and survival in idiopathic pulmonary fibrosis in the era of antifibrotic therapy in Italy: evidence from a longitudinal population study based on healthcare utilization databases","volume":"19","author":"Iommi","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"2026093006115125000_aamag363-B103","doi-asserted-by":"publisher","first-page":"8848919","DOI":"10.1155\/2020\/8848919","article-title":"A clinical model for the prediction of acute exacerbation risk in patients with idiopathic pulmonary fibrosis","volume":"2020","author":"Wu","year":"2020","journal-title":"Biomed Res Int"},{"key":"2026093006115125000_aamag363-B104","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1183\/09031936.00050911","article-title":"Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis","volume":"39","author":"Lee","year":"2012","journal-title":"Eur Resp J"},{"key":"2026093006115125000_aamag363-B105","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s12325-024-03079-2","article-title":"Real-world safety, tolerability and effectiveness of nintedanib in patients with idiopathic pulmonary fibrosis: final report of post-marketing surveillance in Japan","volume":"42","author":"Inoue","year":"2025","journal-title":"Adv Ther"},{"key":"2026093006115125000_aamag363-B106","doi-asserted-by":"publisher","first-page":"e003132","DOI":"10.1136\/bmjopen-2013-003132","article-title":"Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study","volume":"3","author":"Hozumi","year":"2013","journal-title":"BMJ Open"},{"key":"2026093006115125000_aamag363-B107","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3904\/kjim.2023.402","article-title":"Long-term outcome of interstitial lung disease in patients with primary Sj\u00f6gren\u2019s syndrome: a retrospective observational study","volume":"40","author":"Koh","year":"2025","journal-title":"Korean J Intern Med"},{"key":"2026093006115125000_aamag363-B108","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.rmed.2017.05.009","article-title":"Elevated serum D-dimer level is associated with an increased risk of acute exacerbation in interstitial lung disease","volume":"128","author":"Ishikawa","year":"2017","journal-title":"Respir Med"},{"key":"2026093006115125000_aamag363-B109","doi-asserted-by":"publisher","first-page":"106898","DOI":"10.1016\/j.rmed.2022.106898","article-title":"Clinical features of acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: comparison with idiopathic pulmonary fibrosis","volume":"200","author":"Otsuka","year":"2022","journal-title":"Respir Med"},{"key":"2026093006115125000_aamag363-B110","doi-asserted-by":"publisher","first-page":"2202414","DOI":"10.1183\/13993003.02414-2022","article-title":"Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study","volume":"61","author":"Waxman","year":"2023","journal-title":"Eur Respir J"},{"key":"2026093006115125000_aamag363-B111","doi-asserted-by":"publisher","first-page":"e002116","DOI":"10.1136\/bmjresp-2023-002116","article-title":"Inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease with less severe haemodynamics: a post hoc analysis of the INCREASE study","volume":"11","author":"Weatherald","year":"2024","journal-title":"BMJ Open Respir Res"},{"key":"2026093006115125000_aamag363-B112","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12890-021-01530-6","article-title":"Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study","volume":"21","author":"Huang","year":"2021","journal-title":"BMC Pulm Med"},{"key":"2026093006115125000_aamag363-B113","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.rmed.2014.04.009","article-title":"Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis","volume":"108","author":"Ohshimo","year":"2014","journal-title":"Respir Med"},{"key":"2026093006115125000_aamag363-B114","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1080\/14397595.2021.1879346","article-title":"Annual variation rate of KL-6 for predicting acute exacerbation in patients with rheumatoid arthritis\u2013associated interstitial lung disease","volume":"31","author":"Tanaka","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2026093006115125000_aamag363-B115","doi-asserted-by":"publisher","first-page":"e000988","DOI":"10.1136\/bmjopen-2012-000988","article-title":"A cohort study of mortality predictors and characteristics of patients with combined pulmonary fibrosis and emphysema","volume":"2","author":"Kishaba","year":"2012","journal-title":"BMJ Open"},{"key":"2026093006115125000_aamag363-B116","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s40744-021-00371-3","article-title":"The risk factors of exacerbation in interstitial pneumonia with autoimmune features: a single-center observational cohort study","volume":"8","author":"Murata","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2026093006115125000_aamag363-B117","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1183\/09031936.00159709","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome","volume":"37","author":"Song","year":"2011","journal-title":"Eur Respir J"},{"key":"2026093006115125000_aamag363-B118","doi-asserted-by":"publisher","first-page":"e000342","DOI":"10.1136\/bmjresp-2018-000342","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: a 10-year single-centre retrospective study","volume":"5","author":"Yamazoe","year":"2018","journal-title":"BMJ Open Respir Res"},{"key":"2026093006115125000_aamag363-B119","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/bmjresp-2023-001997","article-title":"Clinical manifestations and prognostic factors analysis of patients hospitalised with acute exacerbation of idiopathic pulmonary fibrosis and other interstitial lung diseases","volume":"11","author":"Ba","year":"2024","journal-title":"BMJ Open Respir Res"},{"key":"2026093006115125000_aamag363-B120","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.3390\/diagnostics11091623","article-title":"Differences between acute exacerbations of idiopathic pulmonary fibrosis and other interstitial lung diseases","volume":"11","author":"Faverio","year":"2021","journal-title":"Diagnostics"},{"key":"2026093006115125000_aamag363-B121","doi-asserted-by":"publisher","first-page":"00037","DOI":"10.1183\/23120541.00037-2021","article-title":"Body mass index and in-hospital mortality in patients with acute exacerbation of idiopathic pulmonary fibrosis","volume":"7","author":"Awano","year":"2021","journal-title":"ERJ Open Res"},{"key":"2026093006115125000_aamag363-B122","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/life14010156","article-title":"The impact of chronic comorbidities on outcomes in acute exacerbations of idiopathic pulmonary fibrosis","volume":"14","author":"Baig","year":"2024","journal-title":"Life (Basel)"},{"key":"2026093006115125000_aamag363-B123","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/resp.14643","article-title":"Pulse versus non-pulse corticosteroid therapy in patients with acute exacerbation of idiopathic pulmonary fibrosis","volume":"29","author":"Hyung","year":"2024","journal-title":"Respirology"},{"key":"2026093006115125000_aamag363-B124","doi-asserted-by":"publisher","first-page":"4916","DOI":"10.1038\/s41598-022-08965-9","article-title":"Changes in blood Krebs von den Lungen-6 predict the mortality of patients with acute exacerbation of interstitial lung disease","volume":"12","author":"Choi","year":"2022","journal-title":"Sci Rep"},{"key":"2026093006115125000_aamag363-B125","doi-asserted-by":"publisher","first-page":"12528","DOI":"10.1038\/s41598-023-39101-w","article-title":"Nintedanib administration after the onset of acute exacerbation of interstitial lung disease in the real world","volume":"13","author":"Kato","year":"2023","journal-title":"Sci Rep"},{"key":"2026093006115125000_aamag363-B126","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41598-022-05138-6","article-title":"New risk scoring system for predicting 3-month mortality after acute exacerbation of idiopathic pulmonary fibrosis","volume":"12","author":"Sakamoto","year":"2022","journal-title":"Sci Rep"},{"key":"2026093006115125000_aamag363-B127","doi-asserted-by":"publisher","first-page":"10742","DOI":"10.1038\/s41598-020-67598-y","article-title":"Incidence and impact of extra-pulmonary organ failures on hospital mortality in acute exacerbation of idiopathic pulmonary fibrosis","volume":"10","author":"Zhuang","year":"2020","journal-title":"Sci Rep"},{"key":"2026093006115125000_aamag363-B128","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12890-017-0437-z","article-title":"Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study","volume":"17","author":"Kawamura","year":"2017","journal-title":"BMC Pulm Med"},{"key":"2026093006115125000_aamag363-B129","doi-asserted-by":"publisher","first-page":"e0212810","DOI":"10.1371\/journal.pone.0212810","article-title":"The utility of the Japanese Association for Acute Medicine DIC scoring system for predicting survival in acute exacerbation of fibrosing idiopathic interstitial pneumonia","volume":"14","author":"Yamazaki","year":"2019","journal-title":"PLoS One"},{"key":"2026093006115125000_aamag363-B130","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.resinv.2023.02.006","article-title":"Prognostic value of the qSOFA in patients with acute exacerbation of idiopathic pulmonary fibrosis","volume":"61","author":"Yamazaki","year":"2023","journal-title":"Respir Investig"},{"key":"2026093006115125000_aamag363-B131","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/mr\/roae066","article-title":"Assessing the efficacy of haemoperfusion for dermatomyositis-associated acute exacerbation of interstitial lung disease: a multicentre retrospective study","volume":"35","author":"Sun","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026093006115125000_aamag363-B132","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1164\/rccm.200709-1365OC","article-title":"Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis","volume":"178","author":"Akira","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006115125000_aamag363-B133","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/medicina55050132","article-title":"Possible serological markers to predict mortality in acute exacerbation of idiopathic pulmonary fibrosis","volume":"55","author":"Hachisu","year":"2019","journal-title":"Medicina (Kaunas)"},{"key":"2026093006115125000_aamag363-B134","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/crj.13304","article-title":"Prognosis after acute exacerbation in patients with interstitial lung disease other than idiopathic pulmonary fibrosis","volume":"15","author":"Miyashita","year":"2021","journal-title":"Clin Respir J"},{"key":"2026093006115125000_aamag363-B135","doi-asserted-by":"publisher","first-page":"e31510","DOI":"10.1016\/j.heliyon.2024.e31510","article-title":"HRCT findings predict 1-year mortality in patients with acute exacerbation of idiopathic inflammatory myopathies-associated interstitial lung disease","volume":"10","author":"Zhang","year":"2024","journal-title":"Heliyon"},{"key":"2026093006115125000_aamag363-B136","doi-asserted-by":"publisher","first-page":"7456315","DOI":"10.1155\/2021\/7456315","article-title":"The extent of honeycombing on computed tomography cannot predict the treatment outcome of patients with acute exacerbations of interstitial lung disease","volume":"2021","author":"Nishikawa","year":"2021","journal-title":"Can Respir J"},{"key":"2026093006115125000_aamag363-B137","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/crj.12602","article-title":"Prognostic evaluation by oxygenation with positive end-expiratory pressure in acute exacerbation of idiopathic pulmonary fibrosis: a retrospective cohort study","volume":"12","author":"Suzuki","year":"2018","journal-title":"Clin Respir J"},{"key":"2026093006115125000_aamag363-B138","doi-asserted-by":"publisher","first-page":"9120","DOI":"10.1038\/s41598-021-88718-2","article-title":"Prognostic classification in acute exacerbation of idiopathic pulmonary fibrosis: a multicentre retrospective cohort study","volume":"11","author":"Suzuki","year":"2021","journal-title":"Sci Rep"},{"key":"2026093006115125000_aamag363-B139","doi-asserted-by":"publisher","first-page":"20584601241288502","DOI":"10.1177\/20584601241288502","article-title":"Computed tomography patterns and clinical outcomes of radiation pneumonitis in non-small-cell lung cancer patients","volume":"13","author":"Choi","year":"2024","journal-title":"Acta Radiol Open"},{"key":"2026093006115125000_aamag363-B140","doi-asserted-by":"publisher","first-page":"e0140437","DOI":"10.1371\/journal.pone.0140437","article-title":"Impact of preexisting interstitial lung disease on acute, extensive radiation pneumonitis: retrospective analysis of patients with lung cancer","volume":"10","author":"Ozawa","year":"2015","journal-title":"PLoS One"},{"key":"2026093006115125000_aamag363-B141","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","article-title":"Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review","volume":"43","author":"Roubille","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"2026093006115125000_aamag363-B142","doi-asserted-by":"publisher","first-page":"103335","DOI":"10.1016\/j.autrev.2023.103335","article-title":"The prevalence and effects of treatments of rapidly progressive interstitial lung disease of dermatomyositis\/polymyositis adults: a systematic review and meta-analysis","volume":"22","author":"Wang","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2026093006115125000_aamag363-B143","doi-asserted-by":"publisher","first-page":"1628928","DOI":"10.3389\/fimmu.2025.1628928","article-title":"Associated factors in the development of rapidly progressive interstitial lung disease in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis","volume":"16","author":"Yuan","year":"2025","journal-title":"Front Immunol"},{"key":"2026093006115125000_aamag363-B144","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.chest.2020.01.033","article-title":"Recognition and management of myositis-associated rapidly progressive interstitial lung disease","volume":"158","author":"Jablonski","year":"2020","journal-title":"Chest"},{"key":"2026093006115125000_aamag363-B145","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.amjms.2017.07.013","article-title":"Clinical heterogeneity of interstitial lung disease in polymyositis and dermatomyositis patients with or without specific autoantibodies","volume":"355","author":"Chen","year":"2018","journal-title":"Am J Med Sci"},{"key":"2026093006115125000_aamag363-B146","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/acr.25348","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026093006115125000_aamag363-B147","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006115125000_aamag363-B148","doi-asserted-by":"publisher","first-page":"2500158","DOI":"10.1183\/13993003.00158-2025","article-title":"Update of the international multidisciplinary classification of the interstitial pneumonias: an ERS\/ATS statement","volume":"66","author":"Ryerson","year":"2025","journal-title":"Eur Respir J"},{"key":"2026093006115125000_aamag363-B149","doi-asserted-by":"publisher","first-page":"2102776","DOI":"10.1183\/13993003.02776-2021","article-title":"Drug-induced interstitial lung disease","volume":"60","author":"Spagnolo","year":"2022","journal-title":"Eur Respir J"},{"key":"2026093006115125000_aamag363-B150","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/cid\/cix317","article-title":"Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia","volume":"65","author":"Self","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026093006115125000_aamag363-B151","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jinf.2013.03.003","article-title":"Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study","volume":"67","author":"Musher","year":"2013","journal-title":"J Infect"},{"key":"2026093006115125000_aamag363-B152","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006115125000_aamag363-B153","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006115125000_aamag363-B154","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.resinv.2014.09.003","article-title":"Efficacy of combined corticosteroid and pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis after surgery for lung cancer: a case report","volume":"53","author":"Ohkubo","year":"2015","journal-title":"Respir Investig"},{"key":"2026093006115125000_aamag363-B155","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1111\/jcpt.13819","article-title":"Severe lung injury induced by CD38 monoclonal antibody daratumumab and bortezomib-containing regimen in a patient with preexisting interstitial lung disease: a case report and literature review","volume":"47","author":"Chen","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"2026093006115125000_aamag363-B156","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.ejcts.2007.02.035","article-title":"Mortality and risk factors for surgical lung biopsy in patients with idiopathic interstitial pneumonia","volume":"31","author":"Park","year":"2007","journal-title":"Eur J Cardiothorac Surg"},{"key":"2026093006115125000_aamag363-B157","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1164\/rccm.201508-1632OC","article-title":"In-hospital mortality after surgical lung biopsy for interstitial lung disease in the United States. 2000 to 2011","volume":"193","author":"Hutchinson","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006115125000_aamag363-B158","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.chest.2018.06.027","article-title":"Effect of acute exacerbation of idiopathic pulmonary fibrosis on lung transplantation outcome","volume":"154","author":"Dotan","year":"2018","journal-title":"Chest"},{"key":"2026093006115125000_aamag363-B159","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/thoraxjnl-2020-215681","article-title":"Lung transplantation for acute exacerbation of interstitial lung disease","volume":"77","author":"Chizinga","year":"2022","journal-title":"Thorax"},{"key":"2026093006115125000_aamag363-B160","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s12931-023-02614-z","article-title":"Clinical impact of pre-existing acute exacerbation in patients with interstitial lung disease who underwent lung transplantation","volume":"24","author":"Kim","year":"2023","journal-title":"Respir Res"},{"key":"2026093006115125000_aamag363-B161","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1097\/TP.0000000000004910","article-title":"Impact of acute exacerbation of idiopathic pulmonary fibrosis on lung transplant outcomes","volume":"108","author":"Warrior","year":"2024","journal-title":"Transplantation"},{"key":"2026093006115125000_aamag363-B162","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1159\/000358443","article-title":"Efficacy of azithromycin for treatment of acute exacerbation of chronic fibrosing interstitial pneumonia: a prospective, open-label study with historical controls","volume":"87","author":"Kawamura","year":"2014","journal-title":"Respiration"},{"key":"2026093006115125000_aamag363-B163","doi-asserted-by":"publisher","first-page":"903","DOI":"10.7150\/ijms.4972","article-title":"Procalcitonin-guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis","volume":"10","author":"Ding","year":"2013","journal-title":"Int J Med Sci"},{"key":"2026093006115125000_aamag363-B164","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s13054-023-04682-5","article-title":"Physiological effects of lung-protective ventilation in patients with lung fibrosis and usual interstitial pneumonia pattern versus primary ARDS: a matched-control study","volume":"27","author":"Tonelli","year":"2023","journal-title":"Crit Care"},{"key":"2026093006115125000_aamag363-B165","doi-asserted-by":"publisher","first-page":"240172","DOI":"10.1183\/20734735.0172-2024","article-title":"The use of mechanical ventilation in interstitial lung disease","volume":"21","author":"Nolan","year":"2025","journal-title":"Breathe (Sheff)"},{"key":"2026093006115125000_aamag363-B166","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2169\/internalmedicine.49.3222","article-title":"Noninvasive ventilation in acute exacerbation of idiopathic pulmonary fibrosis","volume":"49","author":"Yokoyama","year":"2010","journal-title":"Intern Med"},{"key":"2026093006115125000_aamag363-B167","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/1471-2466-14-194","article-title":"Non-invasive mechanical ventilation in patients with diffuse interstitial lung diseases","volume":"14","author":"Aliberti","year":"2014","journal-title":"BMC Pulm Med"},{"key":"2026093006115125000_aamag363-B168","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/CPM.0000000000000312","article-title":"Noninvasive oxygenation strategies for acute exacerbation of interstitial lung disease: a retrospective single-center study and a review of the literature","volume":"26","author":"Imai","year":"2019","journal-title":"Clin Pulm Med"},{"key":"2026093006115125000_aamag363-B169","doi-asserted-by":"publisher","first-page":"103","DOI":"10.21037\/jtd.2018.12.114","article-title":"Respiratory management of acute exacerbation of interstitial pneumonia using high-flow nasal cannula oxygen therapy: a single center cohort study","volume":"11","author":"Ito","year":"2019","journal-title":"J Thorac Dis"},{"key":"2026093006115125000_aamag363-B170","doi-asserted-by":"publisher","first-page":"1753466620906327","DOI":"10.1177\/1753466620906327","article-title":"Pulse oximetric saturation to fraction of inspired oxygen (SpO2\/FIO2) ratio 24 hours after high-flow nasal cannula (HFNC) initiation is a good predictor of HFNC therapy in patients with acute exacerbation of interstitial lung disease","volume":"14","author":"Koyauchi","year":"2020","journal-title":"Ther Adv Respir Dis"},{"key":"2026093006115125000_aamag363-B171","doi-asserted-by":"publisher","first-page":"301","DOI":"10.18999\/nagjms.82.2.301","article-title":"High-flow nasal cannula therapy for acute respiratory failure in patients with interstitial pneumonia: a retrospective observational study","volume":"82","author":"Omote","year":"2020","journal-title":"Nagoya J Med Sci"},{"key":"2026093006115125000_aamag363-B172","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4103\/ecdt.ecdt_40_22","article-title":"Noninvasive ventilation in acute exacerbation of interstitial lung diseases","volume":"72","author":"Ahmed","year":"2023","journal-title":"Egypt J Chest Dis Tuberc"},{"key":"2026093006115125000_aamag363-B173","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4103\/ecdt.ecdt_49_23","article-title":"Comparison between nasal high-flow oxygen therapy and noninvasive ventilation on the outcome of patients with chronic interstitial lung disease complicated with acute respiratory failure","volume":"73","author":"Elkheshen","year":"2024","journal-title":"Egypt J Chest Dis Tuberc"},{"key":"2026093006115125000_aamag363-B174","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","article-title":"Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"171","author":"Azuma","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006115125000_aamag363-B175","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"2026093006115125000_aamag363-B176","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS (R) trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir Med"},{"key":"2026093006115125000_aamag363-B177","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12931-019-0977-2","article-title":"Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry","volume":"20","author":"Zurkova","year":"2019","journal-title":"Respir Res"},{"key":"2026093006115125000_aamag363-B178","doi-asserted-by":"publisher","first-page":"148","DOI":"10.36141\/svdld.v37i2.8718","article-title":"A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis","volume":"37","author":"Dhooria","year":"2020","journal-title":"Sarcoidosis Vasc Diff Lung Dis"},{"key":"2026093006115125000_aamag363-B179","doi-asserted-by":"publisher","first-page":"1753466620963015","DOI":"10.1177\/1753466620963015","article-title":"Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients","volume":"14","author":"Feng","year":"2020","journal-title":"Ther Adv Respir Dis"},{"key":"2026093006115125000_aamag363-B180","doi-asserted-by":"publisher","first-page":"21218","DOI":"10.1038\/s41598-020-77837-x","article-title":"Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital","volume":"10","author":"Song","year":"2020","journal-title":"Sci Rep"},{"key":"2026093006115125000_aamag363-B181","doi-asserted-by":"publisher","first-page":"15620","DOI":"10.1038\/s41598-020-72607-1","article-title":"Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis","volume":"10","author":"Kang","year":"2020","journal-title":"Sci Rep"},{"key":"2026093006115125000_aamag363-B182","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1056\/NEJMoa2414108","article-title":"Nerandomilast in patients with idiopathic pulmonary fibrosis","volume":"392","author":"Richeldi","year":"2025","journal-title":"N Engl J Med"},{"key":"2026093006115125000_aamag363-B183","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.resinv.2023.01.007","article-title":"Interstitial pneumonia with autoimmune features and histologic usual interstitial pneumonia treated with anti-fibrotic versus immunosuppressive therapy","volume":"61","author":"Yamano","year":"2023","journal-title":"Respir Investig"},{"key":"2026093006115125000_aamag363-B184","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1136\/thorax-2024-222636","article-title":"Corticosteroid therapy for treating acute exacerbation of interstitial lung diseases: a systematic review","volume":"80","author":"Srivali","year":"2025","journal-title":"Thorax"},{"key":"2026093006115125000_aamag363-B185","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006115125000_aamag363-B186","year":"2026"},{"key":"2026093006115125000_aamag363-B187","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S2213-2600(21)00354-4","article-title":"Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"10","author":"Naccache","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026093006115125000_aamag363-B188","doi-asserted-by":"publisher","first-page":"5275","DOI":"10.21037\/jtd.2018.08.08","article-title":"Effect of cyclosporine A on mortality after acute exacerbation of idiopathic pulmonary fibrosis","volume":"10","author":"Aso","year":"2018","journal-title":"J Thorac Dis"},{"key":"2026093006115125000_aamag363-B189","doi-asserted-by":"publisher","first-page":"116","DOI":"10.36141\/svdld.v36i2.7181","article-title":"Systemic glucocorticoids plus cyclophosphamide for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective nationwide study","volume":"36","author":"Aso","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026093006115125000_aamag363-B190","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/resp.13506","article-title":"Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: a propensity score-matched analysis","volume":"24","author":"Hozumi","year":"2019","journal-title":"Respirology"},{"key":"2026093006115125000_aamag363-B191","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.semarthrit.2021.07.008","article-title":"Intravenous cyclophosphamide in acute exacerbation of rheumatoid arthritis-related interstitial lung disease: a propensity-matched analysis using a nationwide inpatient database","volume":"51","author":"Nakamura","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2026093006115125000_aamag363-B192","doi-asserted-by":"publisher","first-page":"e0260345","DOI":"10.1371\/journal.pone.0260345","article-title":"Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations","volume":"16","author":"Kulkarni","year":"2021","journal-title":"PLoS One"},{"key":"2026093006115125000_aamag363-B193","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12890-024-02957-3","article-title":"Design of the STRIVE-IPF trial\u2014study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis","volume":"24","author":"Kulkarni","year":"2024","journal-title":"BMC Pulm Med"},{"key":"2026093006115125000_aamag363-B194","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12890-015-0004-4","article-title":"Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival","volume":"15","author":"Enomoto","year":"2015","journal-title":"BMC Pulm Med"},{"key":"2026093006115125000_aamag363-B195","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.2169\/internalmedicine.55.6056","article-title":"Survival from an acute exacerbation of idiopathic pulmonary fibrosis with or without direct hemoperfusion with a polymyxin B-immobilized fiber column: a retrospective analysis","volume":"55","author":"Oishi","year":"2016","journal-title":"Intern Med"},{"key":"2026093006115125000_aamag363-B196","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/1753465817708950","article-title":"Efficacy of direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) in rapidly progressive interstitial pneumonias: results of a historical control study and a review of previous studies","volume":"11","author":"Ichiyasu","year":"2017","journal-title":"Ther Adv Respir Dis"},{"key":"2026093006115125000_aamag363-B197","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40560-023-00693-0","article-title":"Polymyxin B-immobilised fibre column treatment for acute exacerbation of idiopathic pulmonary fibrosis patients with mechanical ventilation: a nationwide observational study","volume":"11","author":"Awano","year":"2023","journal-title":"J Intensive Care"},{"key":"2026093006115125000_aamag363-B198","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.2147\/DDDT.S90739","article-title":"Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study","volume":"9","author":"Abe","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"2026093006115125000_aamag363-B199","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1378\/chest.14-2746","article-title":"Recombinant human thrombomodulin in acute exacerbation of idiopathic pulmonary fibrosis","volume":"148","author":"Kataoka","year":"2015","journal-title":"Chest"},{"key":"2026093006115125000_aamag363-B200","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40248-016-0074-z","article-title":"Efficacy of recombinant human soluble thrombomodulin for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a single arm, non-randomized prospective clinical trial","volume":"11","author":"Hayakawa","year":"2016","journal-title":"Multidiscip Respir Med"},{"key":"2026093006115125000_aamag363-B201","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.resinv.2017.10.004","article-title":"Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a historically controlled study","volume":"56","author":"Sakamoto","year":"2018","journal-title":"Respir Investig"},{"key":"2026093006115125000_aamag363-B202","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1164\/rccm.201909-1818OC","article-title":"Thrombomodulin alfa for acute exacerbation of idiopathic pulmonary fibrosis. a randomized, double-blind placebo-controlled trial","volume":"201","author":"Kondoh","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006115125000_aamag363-B203","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12931-019-1037-7","article-title":"Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS trials","volume":"20","author":"Kreuter","year":"2019","journal-title":"Respir Res"},{"key":"2026093006115125000_aamag363-B204","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1111\/crj.12704","article-title":"The effects of pirfenidone in patients with an acute exacerbation of interstitial pneumonia","volume":"12","author":"Matsumura","year":"2018","journal-title":"Clin Respir J"},{"key":"2026093006115125000_aamag363-B205","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1080\/03007995.2019.1565530","article-title":"Pirfenidone improves the survival of patients with idiopathic pulmonary fibrosis hospitalized for acute exacerbation","volume":"35","author":"Vianello","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2026093006115125000_aamag363-B206","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.resinv.2023.01.008","article-title":"Mechanical ventilation for acute exacerbation of fibrosing interstitial lung diseases","volume":"61","author":"Matsunashi","year":"2023","journal-title":"Respir Investig"},{"key":"2026093006115125000_aamag363-B207","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12890-021-01607-2","article-title":"Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications","volume":"21","author":"Kelly","year":"2021","journal-title":"BMC Pulm Med"},{"key":"2026093006115125000_aamag363-B208","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1001\/jama.2023.5355","article-title":"Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials","volume":"329","author":"Maher","year":"2023","journal-title":"JAMA"},{"key":"2026093006115125000_aamag363-B209","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1164\/rccm.202401-0116OC","article-title":"Zinpentraxin alfa for idiopathic pulmonary fibrosis: the randomized phase III STARSCAPE trial","volume":"209","author":"Richeldi","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006115125000_aamag363-B210","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1001\/jama.2024.8693","article-title":"Pamrevlumab for idiopathic pulmonary fibrosis: the ZEPHYRUS-1 randomized clinical trial","volume":"332","author":"Raghu","year":"2024","journal-title":"JAMA"},{"key":"2026093006115125000_aamag363-B211","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1164\/rccm.200703-463PP","article-title":"Acute exacerbations of idiopathic pulmonary fibrosis","volume":"176","author":"Collard","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006115125000_aamag363-B212","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1164\/rccm.202312-2213SO","article-title":"Meaningful endpoints for idiopathic pulmonary fibrosis (IPF) clinical trials: emphasis on \u201cfeels, functions, survives.\u201d Report of a collaborative discussion in a symposium with direct engagement from representatives of patients, investigators, the National Institutes of Health, a patient advocacy organization, and a regulatory agency","volume":"209","author":"Raghu","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006115125000_aamag363-B213","doi-asserted-by":"publisher","first-page":"1601339","DOI":"10.1183\/13993003.01339-2016","article-title":"Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis","volume":"49","author":"Collard","year":"2017","journal-title":"Eur Respir J"},{"key":"2026093006115125000_aamag363-B214","doi-asserted-by":"publisher","first-page":"1901760","DOI":"10.1183\/13993003.01760-2019","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation","volume":"55","author":"Kreuter","year":"2020","journal-title":"Eur Respir J"},{"key":"2026093006115125000_aamag363-B215","doi-asserted-by":"publisher","first-page":"699644","DOI":"10.3389\/fmed.2021.699644","article-title":"Management of acute exacerbation of idiopathic pulmonary fibrosis in specialised and non-specialised ILD centres around the world","volume":"8","author":"Polke","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026093006115125000_aamag363-B216","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1378\/chest.08-0703","article-title":"Seasonal variation: mortality from pulmonary fibrosis is greatest in the winter","volume":"136","author":"Olson","year":"2009","journal-title":"Chest"},{"key":"2026093006115125000_aamag363-B217","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12931-020-01421-0","article-title":"Trends and seasonal variation of hospitalization and mortality of interstitial lung disease in the United States from 2006 to 2016","volume":"21","author":"Ho","year":"2020","journal-title":"Respir Res"},{"key":"2026093006115125000_aamag363-B218","doi-asserted-by":"publisher","first-page":"00636","DOI":"10.1183\/23120541.00636-2023","article-title":"An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis","volume":"10","author":"Ford","year":"2024","journal-title":"ERJ Open Res"},{"key":"2026093006115125000_aamag363-B219","author":"Clinical Trials Arena","year":"2025"},{"key":"2026093006115125000_aamag363-B220","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1164\/rccm.202505-1054ST","article-title":"Approach to the evaluation and management of interstitial lung abnormalities: an official American Thoracic Society clinical statement","volume":"211","author":"Podolanczuk","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006115125000_aamag363-B221","doi-asserted-by":"publisher","first-page":"414","DOI":"10.18553\/jmcp.2016.22.4.414","article-title":"Patterns and economic burden of hospitalizations and exacerbations among patients diagnosed with idiopathic pulmonary fibrosis","volume":"22","author":"Yu","year":"2016","journal-title":"J Manag Care Spec Pharm"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/advance-article-pdf\/doi\/10.1093\/ajrccm\/aamag363\/68777926\/aamag363.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/advance-article-pdf\/doi\/10.1093\/ajrccm\/aamag363\/68777926\/aamag363.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/advance-article-pdf\/doi\/10.1093\/ajrccm\/aamag363\/68777926\/aamag363.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:12:03Z","timestamp":1790763123000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/212\/10\/2358\/8734112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":221,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,7,14]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajrccm\/aamag363","relation":{},"ISSN":["1535-4970"],"issn-type":[{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,7,14]]}}}